Vicor Technologies files Cardiac Analyzer with FDA
This article was originally published in Clinica
Vicor Technologies has filed a 510(k) application with the US FDA for its PD2i algorithm and related Cardiac Analyzer software. The product, called PD2i CA, is designed to identify congestive heart failure patients at increased risk of cardiac death. It does this by analysing the brain's interaction with the heart, using 15 minutes of ECG data. A reduced PD2i value indicates excessive co-ordination of sensory-motor loops that normally regulate heart rhythm – and an imminent risk of sudden cardiac death. The application is based on results from the 537-patient MUSIC trial, which found that the Cardiac Analzyer could predict total mortality, cardiac death and heart failure death. Approval is anticipated in the fourth quarter, Boca Raton, Florida-based Vicor says.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.